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Renal vein thrombosis (RVT) is one of the more com-
mon forms of neonatal thrombosis accounting for
15-20% of systemic thromboembolism[1,2]. A median
age at presentation of 2-3 days have been reported [1,3],
with unilateral and bilateral involvement of renal vein in
89-72% and 28-11% of cases, respectively[4,5]. The clini-
cal presentation of RVT consists of increased kidney
size, macro- or microhematuria, reduced urine output
with some degree of renal failure and thrombocytopenia.
RVT in neonates is a multifactorial disease and it was
associated with coagulopathy, maternal diabetes, birth
asphyxia, sepsis, placement of central venous lines
(CVL) and hereditary thrombophilic factors[5,6]. In
specific, FV 1691G>A mutation and elevated Lp(a) con-
centrations are independent risk factors for the develop-
ment of RVT in neonates. In non-CVL-related RVT,
thrombus formation occurs in the small vessels of the
kidney and may extend into the renal vein and inferior
vena cava. In the neonates with CVL-related RVT, the
thrombus most likely formed first in the vessel adjacent
to the CVL and then extended into the kidney[4]. Renal
ultrasonography shows uni- or bilateral kidney enlarge-
ment with loss of cortico-medullary differentiation and
reduced or absent flow in renal vein[7]. Long-term func-
tional complications include renal insufficiency, renal
tubular dysfunction and hypertension in up to 30% of
patients[1,8]. Controlled data on appropriate clinical
management of neonatal RVT are lacking and recom-
mendations of its treatment are based on low quality
evidence. Current guidelines suggest for unilateral RVT
in the absence of renal impairment or extension into
the inferior vena cava, either 1) supportive care with
radiologic monitoring for extension of thrombosis or
2) anticoagulation with unfractionated heparin (UFH)/
low-molecolar-weight heparin (LMWH) in therapeutic
doses rather than no therapy[9]. For unilateral RVT that
extends into the inferior vena cava, anticoagulation with
UFH/LMWH for a total duration of between 6 weeks
and 3 months is suggested[9]. For bilateral RVT with
evidence of renal impairment, anticoagulation with
UFH/LMWH or initial thrombolytic therapy with tissue
plasminogen activator followed by anticoagulation with
UFH/LMWH is suggested[9].
Renal artery thrombosis (RAT) in the neonate is far less
common than RVT, and there is little information about
its incidence. It is associated with umbilical catheters,
patent ductus arteriosus and hereditary thrombophilia
[10,11]. The clinical presentation is rather silent and renal
ultrasound findings can be minimal unless Doppler ima-
ging is used. The outcome of the affected kidneys is poor
with common global atrophy. For neonates with a periph-
eral arterial catheter-related thrombosis, immediate
removal of the catheter and UFH anticoagulation with or
without thrombolysis or surgical thrombectomy and
microvascular repair with subsequent heparin therapy are
suggested[9].
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